A low prevalence of Parkinson’s disease (PD) has been reported in the Sub-Saharan Africa (SSA) region. The genetic causes and clinical features of PD in this region have been poorly described. Very few reports have examined the availability and access to evidence-based quality care for people living with PD in this region. We reviewed all publications focusing on idiopathic PD from SSA published up to May 2016 and observed a prevalence of PD ranging from 7/100,000 in Ethiopia to 67/100,000 in Nigeria. The most recent community-based study reported a mean age at onset of 69.4 years. The infrequent occurrence of mutations in established PD genes was also observed in the region. Treatments were non-existent or at best irregular. Additionally, there is a lack of well-trained medical personnel and multidisciplinary teams in most countries in this region. Drugs for treating PD are either not available or unaffordable. Large-scale genetic and epidemiological studies are therefore needed in SSA to provide further insights into the roles of genetics and other etiological
factors in the pathogenesis of PD. The quality of care also requires urgent improvement to meet the basic level of care required by PD patients.
Citations
Citations to this article as recorded by
Delivery of Allied Health Therapies to People with Parkinson’s Disease in Africa Roberto Cilia, Marieke C.J. Dekker, Esther Cubo, Mary W. Agoriwo, Elke Kalbe, Bastiaan R. Bloem, Lorraine V. Kalia, Alice Nieuwboer Journal of Parkinson's Disease.2024; 14(s1): S227. CrossRef
The Role of Diet in Parkinson’s Disease Kira N. Tosefsky, Julie Zhu, Yolanda N. Wang, Joyce S.T. Lam, Amanda Cammalleri, Silke Appel-Cresswell, Elke Kalbe, Bastiaan R. Bloem, Lorraine V. Kalia, Alice Nieuwboer Journal of Parkinson's Disease.2024; 14(s1): S21. CrossRef
Advancing genetic testing for neurological disorders in Tanzania: importance, challenges, and strategies for implementation Mohamed Zahir Alimohamed, Angela Augustine Siima, Mohamed Manji Frontiers in Neuroscience.2024;[Epub] CrossRef
Epidemiology of Parkinson’s Disease: An Update Juan R Deliz, Caroline M. Tanner, Paulina Gonzalez-Latapi Current Neurology and Neuroscience Reports.2024; 24(6): 163. CrossRef
Spondias mombin flavonoids showed super-binder ability with downstream molecular targets of Parkinson's disease: A structural study John A. Olanrewaju, Leviticus O. Arietarhire, Oladimeji E. Soremekun, Ezekiel A. Olugbogi, Toluwanimi O. Afolabi, Precious O. Aribisala, Pelumi E. Alege, Abayomi O. Sodipo, Babatunji E. Oyinloye, Olaposi I. Omotuyi Informatics in Medicine Unlocked.2024; 49: 101543. CrossRef
Breaking barriers in Parkinson’s care: the multidisciplinary team approach Zvezdan Pirtošek Journal of Neural Transmission.2024; 131(11): 1349. CrossRef
Structure and process of Parkinson's disease rehabilitation in the southern sector of Ghana: A cross‐sectional survey Mary W. Agoriwo, Conran Joseph, Erika Franzén, Marianne Unger Journal of Evaluation in Clinical Practice.2024;[Epub] CrossRef
Phytoconstituents of Datura metel extract improved motor coordination in haloperidol-induced cataleptic mice: Dual-target molecular docking and behavioural studies Bilqis Abiola Lawal, Yusuf Oloruntoyin Ayipo, Abisola Oyindamola Adekunle, Mohammed Otuofu Amali, Umar Muhammad Badeggi, Waleed A. Alananzeh, Mohd Nizam Mordi Journal of Ethnopharmacology.2023; 300: 115753. CrossRef
Particularités de la Maladie de Parkinson de la personne âgée : expérience du service de gériatrie de Fann à Dakar (Sénégal) A. Sall, M. Ba, R. Djajheté, D. Ba, S. Zaki, M. Coumé NPG Neurologie - Psychiatrie - Gériatrie.2023; 23(134): 85. CrossRef
The Gaps and Prospects of Movement Disorders Education and Research in Africa: A Continental Survey Eman Hamid, Kigocha Okengo, Biniyam A. Ayele, Daniel Gams Massi, Samia Ben Sassi, Houyam Tibar, Sarah Misbah El‐Sadig, Soulaimane Mahoui, Julien Razafimahefa, Ange Eric Kouame‐Assouan, Djibrilla Ben‐Adji, Lengane Y.T. Modeste, Muhyadin Hassan Mohamed, Nes Movement Disorders.2023; 38(2): 178. CrossRef
Transforming Parkinson's Care in Africa (TraPCAf): protocol for a multimethodology National Institute for Health and Care Research Global Health Research Group project R. Walker, N. Fothergill-Misbah, S. Kariuki, O. Ojo, R. Cilia, M. C. J. Dekker, O. Agabi, A. Akpalu, F. Amod, M. Breckons, M. Cham, S. Del Din, C. Dotchin, S. Guggsa, J. Kwasa, D. Mushi, F. O. Nwaokorie, T. Park, L. Rochester, J. Rogathi, F. S. Sarfo, A. BMC Neurology.2023;[Epub] CrossRef
Exploring the levodopa-paradox of freezing of gait in dopaminergic medication-naïve Parkinson’s disease populations Jamie A. F. Jansen, Tamine T. C. Capato, Sirwan K. L. Darweesh, Egberto R. Barbosa, Rogier Donders, Bastiaan R. Bloem, Jorik Nonnekes npj Parkinson's Disease.2023;[Epub] CrossRef
The intestinal luminal sources of α-synuclein: a gastroenterologist perspective Aaron Lerner Nutrition Reviews.2022; 80(2): 282. CrossRef
Surveying Global Availability of Parkinson’s Disease Treatment Zhao H.K. Goh, Julia L.Y. Cheong, Connie Marras, Caroline M. Tanner, Meike Kasten, Amos D. Korczyn, Lana Chahine, Raymond Lo, Alastair J. Noyce Journal of Parkinson's Disease.2022; 12(3): 1023. CrossRef
Current Status of Next-Generation Sequencing Approaches for Candidate Gene Discovery in Familial Parkinson´s Disease Nikita Simone Pillay, Owen A. Ross, Alan Christoffels, Soraya Bardien Frontiers in Genetics.2022;[Epub] CrossRef
Utility of 18F FDG-PET in Parkinsonism in an African population Ferzana Hassan Amod, Ahmed Iqbal Bhigjee, Nozipho Nyakale eNeurologicalSci.2022; 27: 100399. CrossRef
A Narrative Review of Specialist Parkinson’s Nurses: Evolution, Evidence and Expectation Emma Tenison, Alice James, Louise Ebenezer, Emily J. Henderson Geriatrics.2022; 7(2): 46. CrossRef
Treatment with bark extracts of Voacanga africana attenuates motor coordination deficit, depressive-like behavior and microglial reaction, in a mouse model of early Parkinson's disease Salimata Diagne Houndjo, Christophe Melon, Pascal Salin, Abdoulaye Samb, Fatou Bintou Sarr, Lydia Kerkerian-Le Goff, Sylviane Lortet Phytomedicine Plus.2022; 2(3): 100297. CrossRef
Polygenic risk prediction and SNCA haplotype analysis in a Latino Parkinson's disease cohort Douglas P. Loesch, Andrea R.V.R. Horimoto, Elif Irem Sarihan, Miguel Inca-Martinez, Emily Mason, Mario Cornejo-Olivas, Luis Torres, Pilar Mazzetti, Carlos Cosentino, Elison Sarapura-Castro, Andrea Rivera-Valdivia, Angel C. Medina, Elena Dieguez, Victor Ra Parkinsonism & Related Disorders.2022; 102: 7. CrossRef
The impact of COVID‐19 on patients with neurological disorders and their access to healthcare in Africa: A review of the literature Olivier Uwishema, Kristian Steen Frederiksen, Inês F. Silva Correia, Ashraf Mahmoud, Helen Onyeaka, Burhan Dost Brain and Behavior.2022;[Epub] CrossRef
Perspective: Low Risk of Parkinson's Disease in Quasi-Vegan Cultures May Reflect GCN2-Mediated Upregulation of Parkin Mark F McCarty, Aaron Lerner Advances in Nutrition.2021; 12(2): 355. CrossRef
A Rapid Motor Task-Based Screening Tool for Parkinsonism in Community-Based Studies Wendy W. Dlamini, Searles Nielsen, Mwiza Ushe, Gill Nelson, Brad A. Racette Frontiers in Neurology.2021;[Epub] CrossRef
Parkinson disease-associated cognitive impairment Dag Aarsland, Lucia Batzu, Glenda M. Halliday, Gert J. Geurtsen, Clive Ballard, K. Ray Chaudhuri, Daniel Weintraub Nature Reviews Disease Primers.2021;[Epub] CrossRef
Probing the Pre-diagnostic Phase of Parkinson's Disease in Population-Based Studies Lisanne J. Dommershuijsen, Agnita J. W. Boon, M. Kamran Ikram Frontiers in Neurology.2021;[Epub] CrossRef
Medicinal plants for anti-neurodegenerative diseases in West Africa Emmanuel Ayodeji Ayeni, Yuzhou Gong, Hao Yuan, Yikao Hu, Xiaolin Bai, Xun Liao Journal of Ethnopharmacology.2021; : 114468. CrossRef
Mapping the Diverse and Inclusive Future of Parkinson’s Disease Genetics and Its Widespread Impact Inas Elsayed, Alejandro Martinez-Carrasco, Mario Cornejo-Olivas, Sara Bandres-Ciga Genes.2021; 12(11): 1681. CrossRef
Parkinson’s disease – a review of pathogenesis, recent advances in management, and challenges of care in sub-Saharan Africa Akintomiwa I. Makanjuola, Funmilola T. Taiwo, Joseph O. Yaria, Rufus O. Akinyemi, Adesola Ogunniyi Journal of Global Medicine.2021; : e35. CrossRef
Genetics of Parkinson's disease: An introspection of its journey towards precision medicine Sara Bandres-Ciga, Monica Diez-Fairen, Jonggeol Jeff Kim, Andrew B. Singleton Neurobiology of Disease.2020; 137: 104782. CrossRef
Targeted next-generation sequencing identifies novel variants in candidate genes for Parkinson’s disease in Black South African and Nigerian patients Oluwafemi G. Oluwole, Helena Kuivaniemi, Shameemah Abrahams, William L. Haylett, Alvera A. Vorster, Carel J. van Heerden, Colin P. Kenyon, David L. Tabb, Michael B. Fawale, Taofiki A. Sunmonu, Abiodun Ajose, Matthew O. Olaogun, Anastasia C. Rossouw, Ludo BMC Medical Genetics.2020;[Epub] CrossRef
Translation, Validation, Diagnostic Accuracy, and Reliability of Screening Questionnaire for Parkinsonism in Three African Countries Ali Shalash, Njideka U. Okubadejo, Jacques Doumbe, Oluwadamilola O. Ojo, Eman Hamid, Callixte Kuate, Sara Calvo, Asmaa Helmi, Osigwe P. Agabi, Mohamed Essam, Laura Aguado, Hanan Elrassas, Tamer Roushdy, Caroline M. Tanner, Esther Cubo Journal of Parkinson's Disease.2020; 10(3): 1113. CrossRef
Parkinson's Disease Research on the African Continent: Obstacles and Opportunities Marieke C. J. Dekker, Toumany Coulibaly, Soraya Bardien, Owen A. Ross, Jonathan Carr, Morenikeji Komolafe Frontiers in Neurology.2020;[Epub] CrossRef
Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics Benedicta Obenewaa Dankyi, Seth Kwabena Amponsah, Grace Lovia Allotey-Babington, Ismaila Adams, Nana Aboadwe Goode, Henry Nettey Current Therapeutic Research.2020; 93: 100612. CrossRef
Parkinson's disease in Nigeria: A review of published studies and recommendations for future research Oluwafemi G. Oluwole, Helena Kuivaniemi, Jonathan A. Carr, Owen A. Ross, Matthew O.B. Olaogun, Soraya Bardien, Morenikeji A. Komolafe Parkinsonism & Related Disorders.2019; 62: 36. CrossRef
Clinical series of Parkinson's disease in KwaZulu-Natal, South Africa: Retrospective chart review Ferzana Hassan Amod, Ahmed Iqbal Bhigjee Journal of the Neurological Sciences.2019; 401: 62. CrossRef
Frequency of the LRRK2 G2019S mutation in South African patients with Parkinson’s disease Nicola du Toit, Riaan van Coller, David G. Anderson, Jonathan Carr, Soraya Bardien neurogenetics.2019; 20(4): 215. CrossRef
Leucine rich repeat kinase 2 (LRRK2) GLY2019SER mutation is absent in a second cohort of Nigerian Africans with Parkinson disease Njideka U. Okubadejo, Mie Rizig, Oluwadamilola O. Ojo, Hallgeir Jonvik, Olajumoke Oshinaike, Emmeline Brown, Henry Houlden, Hiroyoshi Ariga PLOS ONE.2018; 13(12): e0207984. CrossRef
Motor Symptoms of Parkinson’s Disease – A Review Literature Hilda Aboagyewaa Agyekum Neurophysiology and Rehabilitation.2018; : 38. CrossRef
Aryun Kim, Young Eun Kim, Ji Young Yun, Han-Joon Kim, Hui-Jun Yang, Woong-Woo Lee, Chae Won Shin, Hyeyoung Park, Yu Jin Jung, Ahro Kim, Yoon Kim, Mihee Jang, Beomseok Jeon
J Mov Disord. 2018;11(2):65-71. Published online May 30, 2018
Objective
We examined whether amantadine can prevent the development of dyskinesia.
Methods
Patients with drug-naïve Parkinson’s disease (PD), younger than 70 years of age and in the early stage of PD (Hoehn and Yahr scale < 3), were recruited from April 2011 to December 2014. The exclusion criteria included the previous use of antiparkinsonian medication, the presence of dyskinesia, significant psychological disorders, and previous history of a hypersensitivity reaction. Patients were consecutively assigned to one of 3 treatment groups in an open label fashion: Group A-1, amantadine first and then levodopa when needed; Group A-2, amantadine first, dopamine agonist when needed, and then levodopa; and Group B, dopamine agonist first and then levodopa when needed. The primary endpoint was the development of dyskinesia, which was analyzed by the Kaplan-Meier survival rate.
Results
A total of 80 patients were enrolled: Group A-1 (n = 27), Group A-2 (n = 27), and Group B (n = 26). Twenty-four patients were excluded from the analysis due to the following: withdrawal of amantadine or dopamine agonist (n = 9), alternative diagnosis (n = 2), withdrawal of consent (n = 1), and breach in the protocol (n = 12). After exclusion, 5 of the 56 (8.93%) patients developed dyskinesia. Patients in Group A-1 and A-2 tended to develop dyskinesia less often than those in Group B (cumulative survival rates of 0.933, 0.929, and 0.700 for A-1, A-2, and B, respectively; p = 0.453).
Conclusion
Amantadine as an initial treatment may decrease the incidence of dyskinesia in patients with drug-naïve PD.
Citations
Citations to this article as recorded by
Exploring causal effects of sarcopenia on risk and progression of Parkinson disease by Mendelian randomization Tao Wang, Jiaquan Geng, Xi Zeng, Ruijiang Han, Young Eun Huh, Jiajie Peng npj Parkinson's Disease.2024;[Epub] CrossRef
Investigation of the Long-Term Effects of Amantadine Use in Parkinson’s Disease Sangmin Park, Jung Hwan Shin, Seung Ho Jeon, Chan Young Lee, Han-Joon Kim, Beomseok Jeon Journal of Movement Disorders.2023; 16(2): 224. CrossRef
Polypharmazie bei der Behandlung von Parkinsonsymptomen: eine Nutzen-Risiko Abwägung J. Bedarf, I. Csoti, H. Herbst, P. Urban, D. Woitalla, U. Wüllner DGNeurologie.2023; 6(6): 504. CrossRef
Role of glutamate receptor complex in the organism. Ligands of NMDA receptors in neurodegenerative processes – a modern state of the problem Vladimir D. Dergachev, Ekaterina E. Yakovleva, Eugenii R. Bychkov, Levon B. Piotrovskiy, Petr D. Shabanov Reviews on Clinical Pharmacology and Drug Therapy.2022; 20(1): 17. CrossRef
Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat Imane Frouni, Woojin Kang, Dominique Bédard, Sébastien Belliveau, Cynthia Kwan, Shadi Hadj-Youssef, Élodie Bourgeois-Cayer, Leanne Ohlund, Lekha Sleno, Adjia Hamadjida, Philippe Huot European Journal of Pharmacology.2022; 929: 175090. CrossRef
Amantadine in the treatment of Parkinson’s disease. New opportunities in the context of COVID-19 E.A. Katunina Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2021; 121(4): 101. CrossRef
Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia—Literature Review Michał Hutny, Jagoda Hofman, Aleksandra Klimkowicz-Mrowiec, Agnieszka Gorzkowska Journal of Clinical Medicine.2021; 10(19): 4377. CrossRef
Neuroinflammation and blood–brain barrier disruption following traumatic brain injury: Pathophysiology and potential therapeutic targets Suraj Sulhan, Kristopher A. Lyon, Lee A. Shapiro, Jason H. Huang Journal of Neuroscience Research.2020; 98(1): 19. CrossRef
Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update Sohaila AlShimemeri, Susan H Fox, Naomi P Visanji Expert Opinion on Emerging Drugs.2020; 25(2): 131. CrossRef
Pharmacological Treatment of Early Motor Manifestations of Parkinson Disease (PD) Michelle Ann C. Sy, Hubert H. Fernandez Neurotherapeutics.2020; 17(4): 1331. CrossRef
Gut Microbiota Approach—A New Strategy to Treat Parkinson’s Disease Jing Liu, Fei Xu, Zhiyan Nie, Lei Shao Frontiers in Cellular and Infection Microbiology.2020;[Epub] CrossRef
Viewpoint: Developing drugs for levodopa‐induced dyskinesia in PD: Lessons learnt, what does the future hold? Susan H. Fox, Jonathan M. Brotchie European Journal of Neuroscience.2019; 49(3): 399. CrossRef
Polypharmacy in Parkinson’s disease: risks and benefits with little evidence I. Csoti, H. Herbst, P. Urban, D. Woitalla, U. Wüllner Journal of Neural Transmission.2019; 126(7): 871. CrossRef
Activation of mGlu2/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism Imane Frouni, Adjia Hamadjida, Cynthia Kwan, Dominique Bédard, Vaidehi Nafade, Fleur Gaudette, Stephen G. Nuara, Jim C. Gourdon, Francis Beaudry, Philippe Huot Neuropharmacology.2019; 158: 107725. CrossRef
Can therapeutic strategies prevent and manage dyskinesia in Parkinson’s disease? An update Valentina Leta, Peter Jenner, K. Ray Chaudhuri, Angelo Antonini Expert Opinion on Drug Safety.2019; 18(12): 1203. CrossRef
Objective
Clinicopathological studies over the last decade have broadened the clinical spectrum of progressive supranuclear palsy (PSP) to include several distinct clinical syndromes. We examined the cognitive profiles of patients with PSP-Richardson’s syndrome (PSP-RS) and two atypical ‘brainstem predominant’ PSP phenotypes (PSP-parkinsonism, PSP-P; and PSP-pure akinesia with gait freezing, PSP-PAGF) using a comprehensive neuropsychological battery.
Methods
Fourteen patients diagnosed as PSP-RS, three patients with PSP-P and four patients with PSP-PAGF were assessed using a comprehensive battery of neuropsychological tests.
Results
The typical PSP-RS subgroup demonstrated greater impairments in processing speed [t(19) = -4.10, p = 0.001 (d =1.66)] and executive function [t(19) = -2.63, p = 0.02 (d = 1.20)] compared to the ‘brainstem predominant’ PSP phenotype.
Conclusion
This is the first prospective study to demonstrate that PSP-RS and ‘brainstem predominant’ PSP phenotypes can be differentiated on cognitive grounds. These differences correspond with variations in pathological profiles reported in the literature.
Citations
Citations to this article as recorded by
Pathomechanisms of cognitive impairment in progressive supranuclear palsy Kurt A. Jellinger Journal of Neural Transmission.2023; 130(4): 481. CrossRef
Differential Diagnosis of Rare Subtypes of Progressive Supranuclear Palsy and PSP-Like Syndromes—Infrequent Manifestations of the Most Common Form of Atypical Parkinsonism Patrycja Krzosek, Natalia Madetko, Anna Migda, Bartosz Migda, Dominika Jaguś, Piotr Alster Frontiers in Aging Neuroscience.2022;[Epub] CrossRef
Clinical Spectrum of Tauopathies Nahid Olfati, Ali Shoeibi, Irene Litvan Frontiers in Neurology.2022;[Epub] CrossRef
Neuropsychological assessment could distinguish among different clinical phenotypes of progressive supranuclear palsy: A Machine Learning approach Maria Grazia Vaccaro, Alessia Sarica, Andrea Quattrone, Carmelina Chiriaco, Maria Salsone, Maurizio Morelli, Aldo Quattrone Journal of Neuropsychology.2021; 15(3): 301. CrossRef
“Parkinson’s disease” on the way to progressive supranuclear palsy: a review on PSP-parkinsonism Ján Necpál, Miroslav Borsek, Bibiána Jeleňová Neurological Sciences.2021; 42(12): 4927. CrossRef
The Progressive Supranuclear Palsy: Past and Present Aspects Theodore P. Parthimos, Kleopatra H. Schulpis Clinical Gerontologist.2020; 43(2): 155. CrossRef
Progressive Supranuclear Palsy—Parkinsonism Predominant (PSP-P)—A Clinical Challenge at the Boundaries of PSP and Parkinson's Disease (PD) Piotr Alster, Natalia Madetko, Dariusz Koziorowski, Andrzej Friedman Frontiers in Neurology.2020;[Epub] CrossRef
Objective
To report demographic data from a large cohort of patients with oromandibular dystonia (OMD).
Methods
This is a retrospective review of patients with OMD referred to our institution between 1989 and 2015. Demographic (age of onset, gender, and familial history of dystonia) and clinical (type of OMD, associated dystonia, and etiology of dystonia) data were collected from a cohort of 240 individuals.
Results
The mean age of onset of OMD was 51.6 years old, with a female predominance (2:1). A family history of dystonia was found in 6 patients (2.5%). One hundred and forty-nine patients (62.1%) had the jaw-opening type of OMD, 48 patients (20.0%) had the jaw-closing type, and 43 patients (17.9%) had a mixed form of OMD. Lingual dystonia was also present in 64 (26.7%) of these patients. Eighty-two patients (34.2%) had a focal dystonia, 131 patients (54.6%) had a segmental dystonia, and 27 patients (11.3%) had a generalized dystonia. One hundred and seventy-one patients (71.3%) had idiopathic OMD.
Conclusion
OMD is a chronic and disabling focal dystonia. Our study found a prevalence of female patients, an onset in middle age and a predominantly idiopathic etiology. Unlike other studies, jaw-opening was found to be the most frequent clinical type of OMD.
Citations
Citations to this article as recorded by
Surface electromyography for evaluating patients with oromandibular dystonia Jae-Hyung Kim, Byung-Gook Kim, Yeong-Gwan Im CRANIO®.2024; 42(3): 316. CrossRef
Tongue dystonia as CIS and presenting symptom of multiple sclerosis Farid Shamlou, Narges Ebrahimi, Ahmad Chitsaz Neuroimmunology Reports.2024; 5: 100191. CrossRef
Oromandibular dystonia: from onset to spread a multicenter italian study Assunta Trinchillo, Marcello Esposito, Carmen Terranova, Vincenzo Rizzo, Giovanni Fabbrini, Gina Ferrazzano, Daniele Belvisi, Roberto Erro, Paolo Barone, Francesco Bono, Francesca Di Biasio, Anna Rita Bentivoglio, Christian Lettieri, Maria Concetta Altavi Neurological Sciences.2024; 45(9): 4341. CrossRef
A Case Study of Korean Medicine Treatment in a Patient Complaining of Generalized Dystonia Kyeong-hwa Lee, Hye-min Heo, Dong-joo Kim, Min-jae Kwak, Ye-chae Hwang, Seung-yeon Cho, Jung-mi Park, Chang-nam Ko, Seong-uk Park The Journal of Internal Korean Medicine.2024; 45(2): 208. CrossRef
Oromandibular Dystonia: Clinical and Demographic Data from Eight-Two Patients Mehmet Balal, Meltem Demirkiran Tremor and Other Hyperkinetic Movements.2023;[Epub] CrossRef
Oromandibular Dystonia is a Prominent Feature in Patients with Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency Helio van der Linden Jr., Christiane Cobas, Andre Felipe Pinto Duarte, Marcelo Rodrigues Masruha Journal of Inborn Errors of Metabolism and Screening.2023;[Epub] CrossRef
Clinical Presentation and Management of Peripheral-induced Oromandibular Dystonia in Nigeria: A Case Report and Literature Update Nonso Emmanuel Onyia, Mercy Okoh, Obinna Francis Igwilo, Izegboya Vivian Ukpebor, Eze Stephen Nwauzor Nigerian Journal of Medicine.2023; 32(4): 433. CrossRef
Oromandibular Dystonia – A Systematic Review Udit Saraf, Mitesh Chandarana, K. P Divya, Syam Krishnan Annals of Indian Academy of Neurology.2022; 25(1): 26. CrossRef
Botulinum Toxin Therapy for Oromandibular Dystonia and Other Movement Disorders in the Stomatognathic System Kazuya Yoshida Toxins.2022; 14(4): 282. CrossRef
Botulinum toxin injections in jaw-opening dystonia. The lateral pterygoid – maxillary artery problem Sena Ünal, F. Tugra Karaarslan-Turk, Muhittin Cenk Akbostanci, Elif Peker, Rezzak Yilmaz Journal of Clinical Neuroscience.2022; 101: 217. CrossRef
Oromandibular dystonia seen during pramipexole treatment: A rare case Fatma KARA, Mehmet Fatih GÖL, Ayhan VARLIBAŞ Journal of Surgery and Medicine.2022; 6(6): 1. CrossRef
Dystonia, chorea, hemiballismus and other dyskinesias Matteo Bologna, Josep Valls-Solè, Nitish Kamble, Pramod Kumar Pal, Antonella Conte, Andrea Guerra, Daniele Belvisi, Alfredo Berardelli Clinical Neurophysiology.2022; 140: 110. CrossRef
Movement disorders of the mouth: a review of the common phenomenologies C. M. Ghadery, L. V. Kalia, B. S. Connolly Journal of Neurology.2022; 269(11): 5812. CrossRef
Botulinum Toxin in Movement Disorders: An Update Charenya Anandan, Joseph Jankovic Toxins.2021; 13(1): 42. CrossRef
Temporomandibular disorder–related characteristics and treatment outcomes in Oromandibular Dystonia patients in two different clinical settings: A cross‐sectional study Asha Sude, Joseph Matsumoto, Shanti Kaimal, Ashley Petersen, Donald R. Nixdorf Journal of Oral Rehabilitation.2021; 48(5): 542. CrossRef
Jaw Pain and Oromandibular Dysfunction After a Complex Hospital Course Sarah Smith, Ny-Ying Lam American Journal of Physical Medicine & Rehabilitation.2021; 100(5): e62. CrossRef
Oromandibular Dystonia: A Clinical Examination of 2,020 Cases Laura M. Scorr, Stewart A. Factor, Sahyli Perez Parra, Rachel Kaye, Randal C. Paniello, Scott A. Norris, Joel S. Perlmutter, Tobias Bäumer, Tatiana Usnich, Brian D. Berman, Marie Mailly, Emmanuel Roze, Marie Vidailhet, Joseph Jankovic, Mark S. LeDoux, Ric Frontiers in Neurology.2021;[Epub] CrossRef
Evaluation of Treatment Outcomes in Oromandibular Dystonia Using Surface Electromyography: A Case Series Yeong-Gwan Im, Jae-Hyung Kim, Byung-Gook Kim Journal of Oral Medicine and Pain.2021; 46(4): 143. CrossRef
Application of botulinum toxin in pregnancy and its impact on female reproductive health Wu Li, Min Tang Expert Opinion on Drug Safety.2020; 19(1): 83. CrossRef
Prevalence and clinical characteristics of patients with oromandibular dystonia seen in the orofacial pain clinic: a retrospective study Asha Sude, Donald R. Nixdorf Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.2020; 130(2): 169. CrossRef
Clinical spectrum of focal dystonias: Experience from a tertiary care center Rupesh Prasad, Deepika Joshi, VijayN Mishra, RameshwarN Chaurasia, Abhishek Pathak Annals of Movement Disorders.2020; 3(2): 99. CrossRef
Bite injury related to oromandibular dystonia extending to the maxillary sinus: A case report Yoshiro Koma, Takehiro Fujimoto, Shinji Uejima, Kotaro Sato, Keisuke Sugimoto, Satoshi Yamaguchi, Jun Ishikawa, Kazuya Nambu, Hideharu Hibi Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology.2020; 32(6): 503. CrossRef
Botulinum neurotoxin a therapy efficacy and safety for oromandibular dystonia: a meta-analysis Pariessa D. Dadgardoust, Raymond L. Rosales, Ria Monica Asuncion, Dirk Dressler Journal of Neural Transmission.2019; 126(2): 141. CrossRef
Botulinum Neurotoxin Therapy for Lingual Dystonia Using an Individualized Injection Method Based on Clinical Features Kazuya Yoshida Toxins.2019; 11(1): 51. CrossRef
Oromandibular dystonia, mental distress and oro‐facial dysfunction—A follow‐up 8‐10 years after start of treatment with botulinum toxin Merete Bakke, Sara Baram, Torben Dalager, Heidi Bryde Biernat, Eigild Møller Journal of Oral Rehabilitation.2019; 46(5): 441. CrossRef
Pseudodystonia: A new perspective on an old phenomenon Rok Berlot, Kailash P. Bhatia, Maja Kojović Parkinsonism & Related Disorders.2019; 62: 44. CrossRef
Severe Jaw‐Opening Dystonia as an Unusual Manifestation of Levodopa‐Related Wearing‐Off in Parkinson's Disease, and Successful Treatment With Botulinum Toxin Injection Pankaj Ashok Agarwal Movement Disorders Clinical Practice.2019; 6(6): 500. CrossRef
We present a 47-year-old right-handed woman with a 15-year history of writer’s cramp who was provided with six sessions of cathodal transcranial direct current stimulation (tDCS) combined with observation of writing actions performed by a healthy subject and electromyographic (EMG) biofeedback training to decrease EMG activities in her right forehand muscles while writing for 30 min for 4 weeks. She showed improvement in dystonic posture and writing speed after the intervention. The writing movement and writing speed scores on a writer’s cramp rating scale decreased, along with writing time. Our findings demonstrated that cathodal tDCS combined with action observation and EMG biofeedback training might improve dystonic writing movements in a patient with writer’s cramp.
Citations
Citations to this article as recorded by
Effects of non-invasive brain stimulation in dystonia: a systematic review and meta-analysis Jordan Morrison-Ham, Gillian M. Clark, Elizabeth G. Ellis, Andris Cerins, Juho Joutsa, Peter G. Enticott, Daniel T. Corp Therapeutic Advances in Neurological Disorders.2022;[Epub] CrossRef
New modalities and directions for dystonia care Genko Oyama, Nobutaka Hattori Journal of Neural Transmission.2021; 128(4): 559. CrossRef
The Mini-BESTest is an independent predictor of falls in Parkinson Disease Larissa Karlla Rodrigues Lopes, Aline Alvim Scianni, Lidiane Oliveira Lima, Raquel de Carvalho Lana, Fátima Rodrigues-De-Paula Brazilian Journal of Physical Therapy.2020; 24(5): 433. CrossRef
Modulating Observation-Execution-Related Motor Cortex Activity by Cathodal Transcranial Direct Current Stimulation Fengxue Qi, Michael A. Nitsche, Volker R. Zschorlich Brain Sciences.2019; 9(5): 121. CrossRef
Beyond the target area: an integrative view of tDCS-induced motor cortex modulation in patients and athletes Edgard Morya, Kátia Monte-Silva, Marom Bikson, Zeinab Esmaeilpour, Claudinei Eduardo Biazoli, Andre Fonseca, Tommaso Bocci, Faranak Farzan, Raaj Chatterjee, Jeffrey M. Hausdorff, Daniel Gomes da Silva Machado, André Russowsky Brunoni, Eva Mezger, Luciane Journal of NeuroEngineering and Rehabilitation.2019;[Epub] CrossRef
Purpose less groaning has been reported in advanced progressive supranuclear palsy. We present a case of purposeless groaning occurring as a primary complaint in a patient with advanced Parkinson’s disease. Purposeless groaning is thought to be a manifestation of disinhibition and perseveration due to frontal-subcortical dysfunction. Proper recognition of this phenomenon will help clinicians to avoid unnecessary investigations and treatment (e.g., prescription of opioid medications).
Citations
Citations to this article as recorded by
OFF-Period Purposeless Groaning in Parkinsonism Vikash Agarwal, Jeyalakshmi Rajan, Norlisah Ramli, Cecilia Santiago, Dushyanth B Jasti, Ai Huey Tan, Shen-Yang Lim Neurology India.2022; 70(3): 1232. CrossRef
Involuntary moaning in a Hispanic family with eight affected members Maria Gisatulin, Malco Rossi, Claudia Perandones, Christine Klein, Katja Lohmann, Marcelo Merello Parkinsonism & Related Disorders.2021; 89: 206. CrossRef
Involuntary Groaning Induced by Levodopa Therapy in a Patient With Progressive Supranuclear Palsy Jung E. Park JAMA Neurology.2020; 77(12): 1569. CrossRef
Clinical Phenotype of LRRK2 R1441C in 2 Chinese Sisters Shen-Yang Lim, Jia Lun Lim, Azlina Ahmad-Annuar, Katja Lohmann, Ai Huey Tan, Kai Bin Lim, Yi Wen Tay, Yee Lee Shing, Kalai Arasu Muthusamy, Peter Bauer, Arndt Rolfs, Christine Klein Neurodegenerative Diseases.2020; 20(1): 39. CrossRef
The spectrum of involuntary vocalizations in humans: A video atlas Tina Mainka, Bettina Balint, Felix Gövert, Lille Kurvits, Christoph van Riesen, Andrea A. Kühn, Marina A.J. Tijssen, Andrew J. Lees, Kirsten Müller‐Vahl, Kailash P. Bhatia, Christos Ganos Movement Disorders.2019; 34(12): 1774. CrossRef
We present a case of beta-propeller protein-associated neurodegeneration, a form of neurodegeneration with brain iron accumulation. The patient harbored a novel mutation in the WDR45 gene. A detailed video and description of her clinical condition are provided. Her movement disorder phenomenology was characterized primarily by limb stereotypies and gait dyspraxia. The patient’s disability was advanced by the time iron-chelating therapy with deferiprone was initiated, and no clinical response in terms of cognitive function, behavior, speech, or movements were observed after one year of treatment.
Citations
Citations to this article as recorded by
Metabolic impairments in neurodegeneration with brain iron accumulation Agata Wydrych, Barbara Pakuła, Justyna Janikiewicz, Aneta M. Dobosz, Patrycja Jakubek-Olszewska, Marta Skowrońska, Iwona Kurkowska-Jastrzębska, Maciej Cwyl, Mariola Popielarz, Paolo Pinton, Barbara Zavan, Agnieszka Dobrzyń, Magdalena Lebiedzińska-Arciszew Biochimica et Biophysica Acta (BBA) - Bioenergetics.2025; 1866(1): 149517. CrossRef
Lipid droplet accumulation in Wdr45-deficient cells caused by impairment of chaperone-mediated autophagic degradation of Fasn Qiuhong Xiong, Huimin Sun, Yanlin Wang, Qian Xu, Yu Zhang, Mei Xu, Zhonghua Zhao, Ping Li, Changxin Wu Lipids in Health and Disease.2024;[Epub] CrossRef
L-serine restored lysosomal failure in cells derived from patients with BPAN reducing iron accumulation with eliminating lipofuscin Hye Eun Lee, Minkyo Jung, Kiju Choi, Jae Hyuck Jang, Su-Kyeong Hwang, Sehyun Chae, Jae-Hyeok Lee, Ji Young Mun Free Radical Biology and Medicine.2024; 221: 273. CrossRef
Quantitative retrospective natural history modeling of WDR45-related developmental and epileptic encephalopathy – a systematic cross-sectional analysis of 160 published cases Afshin Saffari, Julian Schröter, Sven F. Garbade, Julian E. Alecu, Darius Ebrahimi-Fakhari, Georg F. Hoffmann, Stefan Kölker, Markus Ries, Steffen Syrbe Autophagy.2022; 18(7): 1715. CrossRef
Cerebral Iron Deposition in Neurodegeneration Petr Dusek, Tim Hofer, Jan Alexander, Per M. Roos, Jan O. Aaseth Biomolecules.2022; 12(5): 714. CrossRef
Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders Rachel M. Wise, Annika Wagener, Urban M. Fietzek, Thomas Klopstock, Eugene V. Mosharov, Fabio A. Zucca, David Sulzer, Luigi Zecca, Lena F. Burbulla Neurobiology of Disease.2022; 175: 105920. CrossRef
WDR45 variants cause ferrous iron loss due to impaired ferritinophagy associated with nuclear receptor coactivator 4 and WD repeat domain phosphoinositide interacting protein 4 reduction Kiwako Tsukida, Shin-ichi Muramatsu, Hitoshi Osaka, Takanori Yamagata, Kazuhiro Muramatsu Brain Communications.2022;[Epub] CrossRef
Iron Chelation in Movement Disorders: Logical or Ironical Dinkar Kulshreshtha, Jacky Ganguly, Mandar Jog Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.2021; : 1. CrossRef
Emerging Disease-Modifying Therapies in Neurodegeneration With Brain Iron Accumulation (NBIA) Disorders Vassilena Iankova, Ivan Karin, Thomas Klopstock, Susanne A. Schneider Frontiers in Neurology.2021;[Epub] CrossRef
Consensus clinical management guideline for beta‐propeller protein‐associated neurodegeneration Jenny L Wilson, Allison Gregory, Manju A Kurian, Ittai Bushlin, Fanny Mochel, Lisa Emrick, Laura Adang, Penelope Hogarth, Susan J Hayflick Developmental Medicine & Child Neurology.2021; 63(12): 1402. CrossRef
WDR45, one gene associated with multiple neurodevelopmental disorders Yingying Cong, Vincent So, Marina A. J. Tijssen, Dineke S. Verbeek, Fulvio Reggiori, Mario Mauthe Autophagy.2021; 17(12): 3908. CrossRef
Towards Precision Therapies for Inherited Disorders of Neurodegeneration with Brain Iron Accumulation Robert V.V. Spaull, Audrey K.S. Soo, Penelope Hogarth, Susan J. Hayflick, Manju A. Kurian Tremor and Other Hyperkinetic Movements.2021;[Epub] CrossRef
The roles of iron and HFE genotype in neurological diseases Yunsung Kim, James R. Connor Molecular Aspects of Medicine.2020; 75: 100867. CrossRef
The Contribution of Iron to Protein Aggregation Disorders in the Central Nervous System Karina Joppe, Anna-Elisa Roser, Fabian Maass, Paul Lingor Frontiers in Neuroscience.2019;[Epub] CrossRef